Ardelyx, Inc.
ARDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001437402
In the last 90 days, Ardelyx, Inc. insiders filed 0 open-market purchases and 8 sales; 251 institutions reported holding it in 13F filings for Q2 2026, worth $906.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $61.6M (15.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 2, 2023 | Feb 28, 2022 |
| Revenue | $407.3M | $333.6M | $124.5M | $52.2M | $10.1M |
| Cost of revenue | $39.5M | $50.6M | $17.8M | $4.12M | $1.00M |
| Research and development | $71.5M | $52.3M | $35.5M | $35.2M | $91.1M |
| Selling, general and administrative | $337.2M | $258.7M | $134.4M | $76.6M | $72.3M |
| Operating income | -$41.0M | -$27.9M | -$63.3M | -$63.8M | -$154.3M |
| Interest expense | – | – | $4.95M | $3.40M | $4.50M |
| Income tax | $969.0K | $266.0K | $547.0K | $8.00K | $4.00K |
| Net income | -$61.6M | -$39.1M | -$66.1M | -$67.2M | -$158.2M |
| EPS, basic | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
| EPS, diluted | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
| Weighted shares, basic | 241.0M | 235.2M | 219.3M | 158.7M | 104.2M |
| Weighted shares, diluted | 241.0M | 235.2M | 219.3M | 158.7M | 104.2M |
| Margins and growth | |||||
| Operating margin | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% |
| Net margin | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% |
| Revenue growth, year over year | +22.1% | +168.1% | +138.6% | +416.6% | +33.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 2, 2023 | Feb 28, 2022 |
| Cash and equivalents | $68.0M | $64.9M | $21.5M | $96.1M | $72.4M |
| Accounts receivable | $71.8M | $57.7M | $22.0M | $7.73M | $502.0K |
| Inventory | $123.1M | $91.2M | $49.5M | $28.3M | – |
| Total current assets | $382.3M | $356.5M | $246.1M | $153.6M | $133.6M |
| Property, plant and equipment | $2.18M | $1.50M | $1.01M | $1.22M | $2.36M |
| Total assets | $501.6M | $435.8M | $297.6M | $190.1M | $149.9M |
| Accounts payable | $19.2M | $16.0M | $11.1M | $10.9M | $4.28M |
| Total current liabilities | $88.6M | $77.8M | $50.4M | $65.6M | $52.8M |
| Long-term debt | $202.8M | $150.9M | $49.8M | $26.7M | $32.3M |
| Total liabilities | $334.7M | $262.5M | $130.8M | $91.7M | $67.3M |
| Shareholders' equity | $166.9M | $173.3M | $166.8M | $98.3M | $82.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 2, 2023 | Feb 28, 2022 |
| Operating cash flow | -$42.5M | -$44.8M | -$89.7M | -$70.0M | -$152.6M |
| Capital expenditures | $1.49M | $1.01M | $344.0K | $55.0K | $1.87M |
| Free cash flow | -$44.0M | -$45.8M | -$90.1M | -$70.1M | -$154.4M |
| Depreciation and amortization | $3.06M | $2.06M | $1.29M | $1.14M | – |
| Stock-based compensation | $49.0M | $37.4M | $13.5M | $10.8M | $12.0M |
| Investing cash flow | -$8.96M | -$18.3M | -$131.2M | $18.4M | $50.9M |
| Financing cash flow | $54.5M | $106.6M | $146.3M | $75.3M | $83.0M |
| Net change in cash | $3.07M | $43.5M | -$74.7M | $23.7M | -$18.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 12.0% | 11.2% | 10.9% | 20.6% | 119.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 27, 2026 | 251.4M | +3.5% | SEC |
| Jul 30, 2026 | 249.2M | +3.4% | SEC |
| Apr 23, 2026 | 247.0M | +3.2% | SEC |
| Feb 12, 2026 | 245.2M | +2.9% | SEC |
| Oct 23, 2025 | 243.0M | +2.6% | SEC |
| Jul 28, 2025 | 241.0M | +2.4% | SEC |
| Apr 24, 2025 | 239.3M | +2.3% | SEC |
| Feb 14, 2025 | 238.4M | +2.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.